

22nd May 2022

13:00-16:00	Short Course - Characterization of Biopharmaceuticals Facilitators: Eef Dirksen, <i>Byondis B.V.</i> , Marta Germano, <i>Janssen Vaccines</i> , and Sigrid Roosendaal, <i>Quality RA B.V.</i>
-------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

23rd May 2022

09:00-09:15	Welcome & Introductions Katarzyna (Kasia) Kozakowska, <i>AstraZeneca</i>
09:15-10:10	Keynote Session I Cutting-Edge Multi-Level Analytical and Structural Characterization of Antibody-Based Therapeutics Alain Beck, <i>Pierre Fabre</i>
10:10-10:40	Networking Break New Member Networking Event
10:40-12:50	Session I: MAM Applications in QC 10:40 - 11:05 Multi-attribute Method Performance Profile for Quality Control of Monoclonal Antibody Therapeutics Eva Vosika, <i>Roche Diagnostics GmbH</i> 11:05 - 11:30 Multi-Attribute Monitoring from Development to Marketing Applications Joseph Mulholland, <i>Janssen</i> 11:30 - 11:55 Considerations for the Application of Multi-attribute-method by Mass Spectrometry (MAM) for QC Release and Stability Testing of Biopharmaceuticals Thomas Pohl, <i>European Federation of Pharmaceutical Industries and Associations (EFPIA)</i> A Perspective on the Contribution of Spectroscopy to Characterising Proteins for Quality Control Alison Rodger, <i>Macquarie University</i>
12:50-13:50	Lunch
13:50-14:50	Roundtable Session 2022 Topics - Table 1: Vaccines Table 2: Stability Table 3: Q2/Q14 Table 4: Analytical Challenges in Development of Novel Modalities Table 5: Why and How to Move New Analytical Technologies from R&D to GMP Table 6: Specs

14:50-15:05	Transition Time
15:05-15:35	Technical Seminar Sponsored by SCIEX
15:35-17:45	<p>Session II: Impact of Impurities and Excipients on Critical Quality Attributes</p> <p>15:35 - 16:00 A Versatile LC-MS based Workflow with Robust 0.1 ppm Sensitivity for Identifying Residual HCPs in Biotherapeutic Products Feng Yang, <i>Genentech, a Member of the Roche Group</i></p> <p>16:00 - 16:25 Assessment of Aspartic Acid Isomerisation and Other Peptide Critical Quality Attributes Vivian Lindo, <i>AstraZeneca</i></p> <p>16:25 - 16:50 Assessing Effects of Leachables and the Quality of Single-Use Systems in Cell Therapy Manufacturing Noemi Dorival-Garcia, <i>The National Institute for Bioprocessing Research and Training (NIBRT)</i></p> <p>16:50 - 17:15 Mechanisms for the Loss of mRNA Activity in Lipid Nanoparticle Delivery Systems Meredith Packer, <i>Tome Biosciences</i></p>
19:00-21:00	Conference Event

24th May 2022

09:00-09:05	Daily Announcements
09:05-11:15	<p>Session III: New Developments in Vaccines</p> <p>09:05 - 09:30 Characterization of mRNA Lipid Nanoparticles Vaccines by Taylor Dispersion Analysis and Capillary Electrophoresis Herve Cottet, <i>Sanofi Pasteur</i></p> <p>09:30 - 09:55 Non-Aqueous Capillary Electrophoresis (CE) for High-Resolution Large RNA Vaccine Analysis Tian Lu, <i>Merck & Co., Inc.</i></p> <p>09:55 - 10:20 Transmission Electron Microscopy (TEM): Utilising a Powerful Tool in Biosafety as a Novel Approach to Characterise the Product Quality of Biologics, Such as Vector-Based Vaccines and Gene Therapy Products Ashley Layland, <i>ZUD</i></p> <p>Accelerating Global Supply of Vaccines: Lessons Learnt Mark Pellett, <i>AstraZeneca</i></p>

11:15-12:15	Poster Session
12:15-13:15	Lunch
13:15-13:45	Technical Seminar Sponsored by Bruker BioSpin
13:45-14:15	Technical Seminar Sponsored by Genovis
14:15-15:10	Keynote Session II The Future is Now: ICH Q14: Analytical Procedure Development and ICH Q2(R2): Analytical Procedure Validation David Keire, <i>CDER, FDA</i>
15:10-15:40	Networking Break
15:40-17:50	Session IV: Regulatory Trends 15:40 - 16:05 Strategies of Overcoming Risk of Changing Analytical Method Gerald Gellermann, <i>Novartis</i> 16:05 - 16:30 Development of New Ph. Eur. “Horizontal” Standards as Multi-Product Analytical Procedures for Monoclonal Antibody Analysis Mihaela Buda, <i>EDQM</i> The Case for Revision to the ICH Stability Guidelines: An Industry Perspective Andrew Lennard, <i>Amgen Inc.</i> Regulatory Experience from the Rolling Review Process and the Conditional Marketing Authorization Process for COVID-19 Vaccines Elisa Pedone, <i>European Medicines Agency</i>
17:50-18:50	Exhibitor Reception

25th May 2022

09:00-09:05	Daily Announcements
09:05-10:00	Keynote Session III Advances in Bioprocessing and Analytics to Accelerate Vaccine Production António Roldão, <i>iBET</i>

10:00-10:25	Networking Break
10:25-11:15	<p>Emerging Professionals Showcase</p> <p>Chemical Mobilization-Based Capillary Isoelectric Focusing Mass Spectrometry Using the nanoCEasy Interface for Pharmaceutical Proteins Analysis Elaheh Naghdi, <i>Aalen University</i></p> <p>Online Native CEX-IM(CIU)-MS to Monitor the Conformational Landscape of Therapeutic Monoclonal Antibody Proteoforms Guusje van Schaick, <i>Leiden University Medical Center</i></p> <p>Site-specific Glycosylation Analysis of the SARS-CoV-2 Spike Yasunori Watanabe, <i>AstraZeneca</i></p> <p>Capillary and Microchip Electrophoresis for Amino Acid Monitoring during Biopharmaceutical Cultivation Leila Josefsson, <i>Kantisto BV</i></p>
11:15-12:15	<p>Polysorbate Workshop Co-lead: Carl Jone, <i>Narwhal Sciences</i> and Harold Taylor, <i>Merz Pharmaceuticals GmbH</i></p> <p>Current State and Common Practices for Handling and Control of Polysorbates for Biopharmaceutical Products Klaus Wuchner, <i>Cilag AG</i></p>
12:15-13:15	Lunch
13:15-15:25	<p>Session V: Novel Technologies & Improvements in Analytical Technologies</p> <p>13:00 - 13:25 Functional Characterization of Antibody Proteoforms using Affinity CE-MS Christoph Gstöttner, <i>Leiden University Medical Center</i></p> <p>13:25 - 13:50 Enabling PAT in Insect Cell Bioprocesses: A Monitoring Toolbox for rAAV Production Inês Isidro, <i>iBET</i></p> <p>13:50 - 14:15 Genome Analysis for Recombinant Adeno Associated Viruses by Capillary Electrophoresis Andrei Hutanu, <i>F. Hoffmann - La Roche Ltd</i></p> <p>14:15 - 14:40 The Fine Art of Destruction for In-Depth Mass Spectrometry-Based Glycoproteomics: Advances in Measurement and Data Analysis — Exploiting the Diagnostic Potential of Fragment Ions Erdmann Rapp, <i>Max Planck Institute</i></p>
15:20-15:30	<p>Closing Remarks Birgit Schmauser, <i>BfArM, Federal Institute for Drugs and Medical Devices</i></p>